Human Lung Fibroblasts

Accelerate your lead compound selection by using a validated human lung fibroblast

Primary, low passage and validated human lung fibroblasts

Available from healthy donor and IPF donor

Validated for high-content, high-sensitivity imaging and advanced image analysis

Human lung fibroblasts to assess the potential of anti-fibrotic therapeutics.

Newcells’ human primary lung fibroblasts undergo rigorous quality controls (QCs) as they form the basis for a high-throughput, high-sensitivity (HTHS) assay.

As part of the quality controls, the lung fibroblasts are tested for their ability to replicate in vitro fibroblast-to-myofibroblast (FMT) transition by stimulation with TGF-β1, mimicking fibroblast activation and extracellular matrix deposition. The fibroblasts are also validated for high-content, high-sensitivity imaging and advanced image analysis.

Application

Lung HTHS FMT assay

Available analytical readouts from assays using activated primary lung fibroblasts

High-throughput Imaging

Cell count
Quantification of extracellular collagen I deposition
Quantification of α-SMA expression
Quantification of α-SMA strand perimeter

Make an enquiry Download Fact sheet

Human Lung Fibroblasts stimulated with TGF-β for 72 hours and immunostained to detect collagen I, as a measure of extracellular matrix production and deposition. — Human Lung Fibroblasts stimulated with TGF-β1 and immunostained to detect extracellular collagen I, as a marker of extracellular matrix deposition.

Origin

Healthy and IPF donor

Assay window

72 h

Lead time

4 to 6 weeks

Applications

High-throughput High Sensitivity (HTHS) FMT Assay (384-well format)

Cell types

Primary human lung fibroblasts

Origin

Human (Healthy donor)
Human (Idiopathic pulmonary fibrosis (IPF) donor)

Services using Newcells’ primary human lung fibroblasts Close Open

Accelerate your compound selection by understanding compound efficacy against fibrosis

Newcells have developed a high-throughput, high-sensitivity model of lung FMT with validated human primary lung fibroblasts for the study of fibroblast activation and extracellular collagen I production following stimulation with the well-established fibrotic mediator, TGF-β1. The assay set-up allows testing of small molecules for their ability to prevent fibroblast activation and ECM deposition. The FMT assay enables further understanding of compound efficacy to advance drug-discovery programs:

Evaluate the effectiveness of therapeutic candidates targeting lung fibrosis
Determine compound efficacy using physiologically relevant assay conditions and high-throughput screening
Gather detailed insights with high-content, high-sensitivity imaging and advanced image analysis

Validated Human Lung Fibroblast model Close Open

Primary, low passage, fibroblasts isolated from adult donor lung tissue (healthy donor or IPF-diseased donor)
Validated donors respond to TGF-β1 stimulation and reproducibly undergo lung FMT
Assay setup uses multiple donors to better evaluate donor-to-donor variability

Human lung fibroblast description Close Open

Low passage normal human primary fibroblasts isolated from adult lung tissue
Available from multiple donors including both healthy and IPF donors

Images

Fibroblasts to Myofibroblast transition — Human Lung Fibroblasts stimulated with TGF-β1 and immunostained to detect α-SMA, as a measure of fibroblast to myofibroblast transition.

How to use our primary lung fibroblast model?

Outsource your experiments to us

Take advantage of our expertise: with our fast and reliable service, our in-house experts collaborate with you to design experiments focused on your hypothesis. Performed at our cutting-edge facilities by our team of lung experts, our fast and reliable service provides study data that presents key insights into the ability of anti-fibrotic therapeutics to reduce fibroblast activation and matrix deposition in - vivo

Contact an expert

Newcells Biotech's HTHS FMT Assay

Our high-throughput, high-sensitivity assay permits the screening of multiple, anti-fibrotic test articles over a range of concentrations. Our streamlines process generates experimental readouts within 4-6 weeks from study initiation. The assay set-up allows testing of small molecules for their ability to prevent fibroblast activation and ECM deposition across multiple concentrations. Through multiplexed detection methods, we can simultaneously quantify cell number, α-SMA expression, α-SMA strand perimeter and extracellular collagen I deposition, maximizing experimental yields.

Find out more

Contact us

Is this the model for you? Speak to one of our experts about your requirements.

Make an Enquiry

Human Lung Fibroblasts